NCT06969001View on ClinicalTrials.gov

Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

September 4, 2025

Study Completion Date

September 4, 2025

Conditions
Wet Age Related Macular Degeneration
Interventions
DRUG

SCAI-005 0.04% or placebo

axitinib 0.014mg or placebo

DRUG

SCAI-005 0.08% or placebo

axitinib 0.028mg or placebo

DRUG

SCAI-005 0.08% or placebo 2drops

axitinib 0.056mg or placebo

Trial Locations (1)

Unknown

The Catholic University, Seoul ST. Mary's Hospital, Seoul

All Listed Sponsors
lead

SCAI Therapeutics

INDUSTRY